Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gout drug may take the sting out of knee replacement recovery

NCT ID NCT06936709

Symptom relief Sponsor: Geisinger Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This trial tests whether colchicine, an anti-inflammatory drug used for gout, can reduce pain after total knee replacement surgery. Adults having knee replacement for osteoarthritis will take colchicine or a placebo for a few days after surgery. Researchers will track pain scores and opioid use to see if colchicine helps people recover with less discomfort.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
colchicine
What this could lead to
If colchicine works, it could offer a new way to manage pain after knee replacement, potentially reducing the need for opioids.
What could go wrong
This is a small, early-stage trial. Colchicine may not reduce pain more than a placebo, and it can cause side effects like stomach upset.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients 18 years or older undergoing elective total knee arthroplasty for osteoarthritis. Exclusion Criteria: * Subject has impaired hepatic function (Child-Pugh Class \>B) * Subject has impaired renal function (GFR \< 60 ml/min/1.73 m2) * Subject has known adverse reaction to colchicine * Subject has chronic opioid use (Filled opioid medication twice within 6 months of surgical date) * Subject is pregnant or expecting to become pregnant during the time of the study associated with colchicine exposure (postoperative days 0-3) * Subject is unable to provide informed consent * Subject is actively prescribed medication that interact with colchicine in a manner that would increase the risk of colchicine toxicity, i.e.: * Antifungals: Ketoconazole, itraconazole, fluconazole, etc… * Macrolides : Clarithromycin, erythromycin * HIV protease : Ritonavir, Atazanavir, saquinavir, etc... * Ca2+: Verapamil and Diltiazem * Cyclosporine * Danazol * Amiodorone * Quinidine * Anti-hepaciviral combinations * Grapefruit juice * Statins: atorvastatin, lovastatin, simvastatin, etc… * Gemfibrozil and other fibrates * Digoxin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoarthritis of knee are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis susceptibility 6 osteoarthritis, knee Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteoarthritis of knee Perioperative pain control Recovery following primary total knee arthroplasty

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.